Tissue factor activity in patients with systemic lupus erythematosus: Association with disease activity

Research output: Contribution to journalArticle

Abstract

Objective. Tissue factor (TF) is the major intrinsic initiator of clotting. TF expression on monocytes has been associated with high titers of anticardiolipin antibodies (aCL) in patients with antiphospholipid syndrome (APS) with thrombosis. We investigated the influence of clinical factors on TF activity in blood from patients with systemic lupus erythematosus (SLE) and examined the relationship between aCL and TF. Methods. In this cross sectional study, consecutive patients with SLE from one rheumatology clinic gave blood samples for measurement of TF activity, aCL, and Russell viper venom time. We assessed disease activity by measuring sedimentation rate, anti-dsDNA, and complement components C3 and C4, and measured clinical indices. Associations were investigated with the Wilcoxon rank-sum test and linear regression. Results. Sixty-nine patients contributed blood samples. The median age was 38 years, and 10 of the SLE patients had a history of thrombosis. Patients with active arthritis had TF activity 1.3 times that in patients without arthritis (p = 0.028). Users of nonsteroidal antiinflammatory drugs (NSAID) had TF activity significantly lower than nonusers (p = 0.010). Patients with previous thrombosis had TF activity significantly lower than patients without thrombosis (p <0.001). Overall, aCL and TF activity were not associated when we adjusted for these clinical factors. Conclusion. Arthritis, previous thrombosis, and use of NSAID significantly modified TF activity in patients with SLE. Unlike previous reports, we found no association between aCL titer and TF activity, which may be due to our adjusting for other important clinical factors.

Original languageEnglish (US)
Pages (from-to)2827-2832
Number of pages6
JournalJournal of Rheumatology
Volume27
Issue number12
StatePublished - 2000
Externally publishedYes

Fingerprint

Thromboplastin
Systemic Lupus Erythematosus
Anticardiolipin Antibodies
Thrombosis
Arthritis
Nonparametric Statistics
Anti-Inflammatory Agents
Complement C4
Complement C3
Antiphospholipid Syndrome
Prothrombin Time
Rheumatology
Pharmaceutical Preparations
Monocytes
Linear Models
Cross-Sectional Studies

Keywords

  • Anticardiolipin antibodies
  • Systemic lupus erythematosus
  • Tissue factor

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

@article{3a142c29813c49f4950f09fbee1db351,
title = "Tissue factor activity in patients with systemic lupus erythematosus: Association with disease activity",
abstract = "Objective. Tissue factor (TF) is the major intrinsic initiator of clotting. TF expression on monocytes has been associated with high titers of anticardiolipin antibodies (aCL) in patients with antiphospholipid syndrome (APS) with thrombosis. We investigated the influence of clinical factors on TF activity in blood from patients with systemic lupus erythematosus (SLE) and examined the relationship between aCL and TF. Methods. In this cross sectional study, consecutive patients with SLE from one rheumatology clinic gave blood samples for measurement of TF activity, aCL, and Russell viper venom time. We assessed disease activity by measuring sedimentation rate, anti-dsDNA, and complement components C3 and C4, and measured clinical indices. Associations were investigated with the Wilcoxon rank-sum test and linear regression. Results. Sixty-nine patients contributed blood samples. The median age was 38 years, and 10 of the SLE patients had a history of thrombosis. Patients with active arthritis had TF activity 1.3 times that in patients without arthritis (p = 0.028). Users of nonsteroidal antiinflammatory drugs (NSAID) had TF activity significantly lower than nonusers (p = 0.010). Patients with previous thrombosis had TF activity significantly lower than patients without thrombosis (p <0.001). Overall, aCL and TF activity were not associated when we adjusted for these clinical factors. Conclusion. Arthritis, previous thrombosis, and use of NSAID significantly modified TF activity in patients with SLE. Unlike previous reports, we found no association between aCL titer and TF activity, which may be due to our adjusting for other important clinical factors.",
keywords = "Anticardiolipin antibodies, Systemic lupus erythematosus, Tissue factor",
author = "Jodi Segal and Kickler, {Thomas Stephen} and Michelle Petri",
year = "2000",
language = "English (US)",
volume = "27",
pages = "2827--2832",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "12",

}

TY - JOUR

T1 - Tissue factor activity in patients with systemic lupus erythematosus

T2 - Association with disease activity

AU - Segal, Jodi

AU - Kickler, Thomas Stephen

AU - Petri, Michelle

PY - 2000

Y1 - 2000

N2 - Objective. Tissue factor (TF) is the major intrinsic initiator of clotting. TF expression on monocytes has been associated with high titers of anticardiolipin antibodies (aCL) in patients with antiphospholipid syndrome (APS) with thrombosis. We investigated the influence of clinical factors on TF activity in blood from patients with systemic lupus erythematosus (SLE) and examined the relationship between aCL and TF. Methods. In this cross sectional study, consecutive patients with SLE from one rheumatology clinic gave blood samples for measurement of TF activity, aCL, and Russell viper venom time. We assessed disease activity by measuring sedimentation rate, anti-dsDNA, and complement components C3 and C4, and measured clinical indices. Associations were investigated with the Wilcoxon rank-sum test and linear regression. Results. Sixty-nine patients contributed blood samples. The median age was 38 years, and 10 of the SLE patients had a history of thrombosis. Patients with active arthritis had TF activity 1.3 times that in patients without arthritis (p = 0.028). Users of nonsteroidal antiinflammatory drugs (NSAID) had TF activity significantly lower than nonusers (p = 0.010). Patients with previous thrombosis had TF activity significantly lower than patients without thrombosis (p <0.001). Overall, aCL and TF activity were not associated when we adjusted for these clinical factors. Conclusion. Arthritis, previous thrombosis, and use of NSAID significantly modified TF activity in patients with SLE. Unlike previous reports, we found no association between aCL titer and TF activity, which may be due to our adjusting for other important clinical factors.

AB - Objective. Tissue factor (TF) is the major intrinsic initiator of clotting. TF expression on monocytes has been associated with high titers of anticardiolipin antibodies (aCL) in patients with antiphospholipid syndrome (APS) with thrombosis. We investigated the influence of clinical factors on TF activity in blood from patients with systemic lupus erythematosus (SLE) and examined the relationship between aCL and TF. Methods. In this cross sectional study, consecutive patients with SLE from one rheumatology clinic gave blood samples for measurement of TF activity, aCL, and Russell viper venom time. We assessed disease activity by measuring sedimentation rate, anti-dsDNA, and complement components C3 and C4, and measured clinical indices. Associations were investigated with the Wilcoxon rank-sum test and linear regression. Results. Sixty-nine patients contributed blood samples. The median age was 38 years, and 10 of the SLE patients had a history of thrombosis. Patients with active arthritis had TF activity 1.3 times that in patients without arthritis (p = 0.028). Users of nonsteroidal antiinflammatory drugs (NSAID) had TF activity significantly lower than nonusers (p = 0.010). Patients with previous thrombosis had TF activity significantly lower than patients without thrombosis (p <0.001). Overall, aCL and TF activity were not associated when we adjusted for these clinical factors. Conclusion. Arthritis, previous thrombosis, and use of NSAID significantly modified TF activity in patients with SLE. Unlike previous reports, we found no association between aCL titer and TF activity, which may be due to our adjusting for other important clinical factors.

KW - Anticardiolipin antibodies

KW - Systemic lupus erythematosus

KW - Tissue factor

UR - http://www.scopus.com/inward/record.url?scp=0033673047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033673047&partnerID=8YFLogxK

M3 - Article

C2 - 11128671

AN - SCOPUS:0033673047

VL - 27

SP - 2827

EP - 2832

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 12

ER -